Today: 8 July 2026

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

Vertex stock jumps 4% as earnings date nears — what traders watch next for VRTX

New York, Jan 22, 2026, 05:11 EST — Premarket Vertex Pharmaceuticals shares jumped 4.31%, closing Wednesday at $461.14 and marking their third straight session of gains. Trading volume climbed past the stock’s 50-day average. VRTX outperformed peers like AbbVie, Krystal Biotech, and Arcturus Therapeutics, while the S&P 500 and Dow each gained over 1%.
22 January 2026
···
FedEx stock gets a tug-of-war: downgrade meets $350–$355 targets as freight spin-off looms

FedEx stock gets a tug-of-war: downgrade meets $350–$355 targets as freight spin-off looms

Rothschild & Co Redburn lowered its rating on FedEx to Neutral from Buy, arguing that the stock’s current valuation already “fairly reflect[s]” the expected value from the planned spin-off of its freight division. The move follows a solid rally in FedEx shares, which have climbed roughly 37% over the last three months. The stock has hovered just below its 52-week peak, data from Investing.com shows.
22 January 2026
·
Beazley Rejects Zurich’s $10bn Takeover Bid as Lloyd’s Plan B Takes Shape

Beazley Rejects Zurich’s $10bn Takeover Bid as Lloyd’s Plan B Takes Shape

Beazley turned down Zurich Insurance’s all-cash bid on Thursday, calling the 1,280 pence-per-share offer a “material undervaluation” of the company and its future as an independent firm. Shares of the London-listed specialty insurer fell roughly 3% in early trading. The refusal comes as Zurich pushes to expand its specialty insurance footprint—covering unique risks like cyber attacks, marine, and aviation—and amid growing chatter about deals in the London market. Zurich’s bid priced Beazley at a 56% premium over its pre-offer closing price. Shares of London peers Hiscox and Lancashire climbed earlier this week, fueled by speculation of more mergers ahead. Jefferies analysts called the premium “generous,” but highlighted Beazley’s strong cyber business and solid returns.
22 January 2026
·
Future plc snaps up SheerLuxe for £39.9m as buyback rolls on and Fidelity lifts stake

Future plc snaps up SheerLuxe for £39.9m as buyback rolls on and Fidelity lifts stake

Future announced Thursday it will acquire UK digital publisher SheerLuxe, along with BLUSH Talent MGMT, for an initial £39.9 million in cash. Shares jumped 3.7% to 525.5 pence by 0835 GMT, per Fidelity data. The timing of the deal is tricky for Future, coming after a steep decline in its stock price. Shares have fallen over 40% in the last year and are hovering close to their 52-week lows, per data from Investing.com.
22 January 2026
Diageo share price climbs in London as Barclays, Jefferies stick with Buy calls ahead of Feb 25 results

Diageo share price climbs in London as Barclays, Jefferies stick with Buy calls ahead of Feb 25 results

London, Jan 22, 2026, 09:33 GMT — Regular session Diageo shares climbed roughly 0.5% to about 1,681 pence in early London trading Thursday, continuing a bounce that pushed the stock up 2.6% the previous day. Despite this, the world’s biggest spirits producer remains down around 31% over the last year, making it vulnerable to any signs of stabilizing demand.
22 January 2026
·
Lloyds shares are above £1 again — UBS lifts target as investors do the dividend maths

Lloyds shares are above £1 again — UBS lifts target as investors do the dividend maths

Lloyds Banking Group shares climbed 1.8% to 103.25 pence in early London trading Thursday, approaching the upper end of a 52-week range between 60.36p and 103.55p. At 103.25p, the stock is hovering just above the £1 mark—a psychological threshold closely watched for the UK lender. The move comes just a week before Lloyds’ full-year results, scheduled for Jan. 29. Investors will be keenly watching for 2026 guidance and hints about what follows the 2022–26 strategic plan. UBS lifted its price target to 103p from 90p but held firm on a neutral rating, citing uncertainties around growth after 2026 and valuations following the recent rally. UBS projects Lloyds could deliver around 25% year-on-year growth in pre-provision profit by 2026—excluding motor finance remediation costs and before loan-loss charges—driven by about 8% growth in net interest income and modest cost inflation.
22 January 2026
··
Rolls-Royce shares rebound after a wobble as investors size up the 2026 trade

Rolls-Royce shares rebound after a wobble as investors size up the 2026 trade

Rolls-Royce shares climbed 0.8% to 1,264.5 pence in early London trading Thursday, rebounding after a 2.03% fall on Wednesday that closed the stock at £12.55. The dip came even as the FTSE 100 inched up 0.11%, with trading volume in Rolls-Royce staying below its recent average. https://www.investing.com/equities/rolls-royce https://www.marketwatch.com/data-news/rolls-royce-holdings-slips-wednesday-underperforms-market-81017ad1-30851936a88e The modest rebound casts a sharp spotlight on a stock that’s come to symbolize the UK market’s aerospace and defence rally. Interactive Investor contributor Robert Stephens pointed out the Aerospace & Defence sector has jumped 91% over the past year, compared to a 20% rise for the broader market. He also highlighted Rolls-Royce’s forward price/earnings ratio of 44.2 — a stark contrast to the FTSE 350’s 18.7, reflecting higher expected earnings pricing. https://www.ii.co.uk/analysis-commentary/sector-screener-why-rolls-royce-shares-still-appeal-ii537855
22 January 2026
1 … 791 792 793 794 795 … 2,151

Stock Market Today

  • AstraZeneca (LSE:AZN) Seen 13% Below Fair Value as Oncology Deals Expand
    July 8, 2026, 12:54 PM EDT. AstraZeneca (LSE:AZN) is trading at £143.64, nearly 13% under a fair value estimate of £164.85. The drugmaker's growing push in oncology and siRNA partnerships and a late-stage pipeline in cancer, rare diseases, and heart drugs are seen driving more than $10 billion in potential risk-adjusted peak sales. Shares are up 3.65% over 30 days but down 5.6% over the last 90 days. Total shareholder return for one year is solid at 41.34%. Key risks include pricing pressure and heavy reliance on blockbuster drugs, both of which could weigh on valuation. AstraZeneca trades at 28.7x earnings, well above the sector average of 12.3x, pricing in hopes for further growth.
Go toTop